225 related articles for article (PubMed ID: 9598779)
1. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.
Schmitz FJ; Hofmann B; Hansen B; Scheuring S; Lückefahr M; Klootwijk M; Verhoef J; Fluit A; Heinz HP; Köhrer K; Jones ME
J Antimicrob Chemother; 1998 Apr; 41(4):481-4. PubMed ID: 9598779
[TBL] [Abstract][Full Text] [Related]
2. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
[TBL] [Abstract][Full Text] [Related]
3. Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC.
Schmitz FJ; Jones ME; Hofmann B; Hansen B; Scheuring S; Lückefahr M; Fluit A; Verhoef J; Hadding U; Heinz HP; Köhrer K
Antimicrob Agents Chemother; 1998 May; 42(5):1249-52. PubMed ID: 9593159
[TBL] [Abstract][Full Text] [Related]
4. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.
Ng EY; Trucksis M; Hooper DC
Antimicrob Agents Chemother; 1996 Aug; 40(8):1881-8. PubMed ID: 8843298
[TBL] [Abstract][Full Text] [Related]
5. [In vitro activity of new quinolones against clinical strains of Staphylococcus aureus of the wild type and with mutations characterized by gyrA, gyrB and grlA].
Yagüe Guirao G; Martínez-Toldos MC; Alonso Manzanares MA; Gutiérrez Zufiaurre MN; Martínez-Andrés JA; Muñoz Bellido JL; García-Rodríguez JA; Segovia Hernández M
Rev Esp Quimioter; 2000 Sep; 13(3):271-5. PubMed ID: 11086276
[TBL] [Abstract][Full Text] [Related]
6. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.
Schmitz FJ; Fluit AC; Brisse S; Verhoef J; Köhrer K; Milatovic D
FEMS Immunol Med Microbiol; 1999 Dec; 26(3-4):281-7. PubMed ID: 10575140
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of 13 fluoroquinolones against Staphylococcus aureus isolates with characterized mutations in gyrA, gyrB, grlA, and norA and against wild-type isolates.
Muñoz Bellido JL; Alonso Manzanares MA; Yagüe Guirao G; Gutiérrez Zufiaurre MN; Toldos MC; Segovia Hernández M; Garcia-Rodríguez JA
Antimicrob Agents Chemother; 1999 Apr; 43(4):966-8. PubMed ID: 10103212
[TBL] [Abstract][Full Text] [Related]
8. Characterization of gyrA, gyrB, grlA and grlB mutations in fluoroquinolone-resistant clinical isolates of Staphylococcus aureus.
Takahashi H; Kikuchi T; Shoji S; Fujimura S; Lutfor AB; Tokue Y; Nukiwa T; Watanabe A
J Antimicrob Chemother; 1998 Jan; 41(1):49-57. PubMed ID: 9511037
[TBL] [Abstract][Full Text] [Related]
9. Correlation between the activity of different fluoroquinolones and the presence of mechanisms of quinolone resistance in epidemiologically related and unrelated strains of methicillin-susceptible and -resistant Staphylococcus aureus.
Sierra JM; Marco F; Ruiz J; Jiménez de Anta MT; Vila J
Clin Microbiol Infect; 2002 Dec; 8(12):781-90. PubMed ID: 12519351
[TBL] [Abstract][Full Text] [Related]
10. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
Ferrero L; Cameron B; Manse B; Lagneaux D; Crouzet J; Famechon A; Blanche F
Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
[TBL] [Abstract][Full Text] [Related]
11. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus.
Schmitz FJ; Fluit AC; Lückefahr M; Engler B; Hofmann B; Verhoef J; Heinz HP; Hadding U; Jones ME
J Antimicrob Chemother; 1998 Dec; 42(6):807-10. PubMed ID: 10052906
[TBL] [Abstract][Full Text] [Related]
12. Small-colony mutants of Staphylococcus aureus allow selection of gyrase-mediated resistance to dual-target fluoroquinolones.
Pan XS; Hamlyn PJ; Talens-Visconti R; Alovero FL; Manzo RH; Fisher LM
Antimicrob Agents Chemother; 2002 Aug; 46(8):2498-506. PubMed ID: 12121924
[TBL] [Abstract][Full Text] [Related]
13. Characterization of sparfloxacin-resistant mutants of Staphylococcus aureus obtained in vitro.
Ruiz J; Sierra JM; De Anta MT; Vila J
Int J Antimicrob Agents; 2001 Aug; 18(2):107-12. PubMed ID: 11516932
[TBL] [Abstract][Full Text] [Related]
14. In-vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram-negative bacilli and Enterococcus faecalis.
Tankovic J; Bachoual R; Ouabdesselam S; Boudjadja A; Soussy CJ
J Antimicrob Chemother; 1999 May; 43 Suppl B():19-23. PubMed ID: 10382871
[TBL] [Abstract][Full Text] [Related]
15. Increased antibacterial activity of DW286, a novel fluoronaphthyridone antibiotic, against Staphylococcus aureus strains with defined mutations in DNA gyrase and topoisomerase IV.
Yun HJ; Min YH; Jo YW; Shim MJ; Choi EC
Int J Antimicrob Agents; 2005 Apr; 25(4):334-7. PubMed ID: 15784314
[TBL] [Abstract][Full Text] [Related]
16. Association of mutations in grlA and gyrA topoisomerase genes with resistance to ciprofloxacin in epidemic and sporadic isolates of methicillin-resistant Staphylococcus aureus.
Deplano A; Zekhnini A; Allali N; Couturier M; Struelens MJ
Antimicrob Agents Chemother; 1997 Sep; 41(9):2023-5. PubMed ID: 9303407
[TBL] [Abstract][Full Text] [Related]
17. Detection of mutations in quinolone resistance-determining regions in levofloxacin- and methicillin-resistant Staphylococcus aureus: effects of the mutations on fluoroquinolone MICs.
Horii T; Suzuki Y; Monji A; Morita M; Muramatsu H; Kondo Y; Doi M; Takeshita A; Kanno T; Maekawa M
Diagn Microbiol Infect Dis; 2003 Jun; 46(2):139-45. PubMed ID: 12812718
[TBL] [Abstract][Full Text] [Related]
18. Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus.
Takahata M; Yonezawa M; Kurose S; Futakuchi N; Matsubara N; Watanabe Y; Narita H
J Antimicrob Chemother; 1996 Sep; 38(3):543-6. PubMed ID: 8889728
[TBL] [Abstract][Full Text] [Related]
19. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.
Fournier B; Hooper DC
Antimicrob Agents Chemother; 1998 Jan; 42(1):121-8. PubMed ID: 9449271
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.
Jones ME; Critchley IA; Karlowsky JA; Blosser-Middleton RS; Schmitz FJ; Thornsberry C; Sahm DF
Antimicrob Agents Chemother; 2002 Jun; 46(6):1651-7. PubMed ID: 12019071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
